DWA
UTHR icon

Dorsey Wright & Associates’s United Therapeutics UTHR Stock Holding History

Dorsey Wright & Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.9M Sell
5,354
-5,613
-51% -$3.16M 0.49% 60
2026
Q1 		$6.5M Buy
10,967
+5,839
+114% +$2.91M 0.81% 44
2025
Q4 		$2.5M Buy
+5,128
New +$2.39M 0.54% 63
2025
Q1 		– Sell
-5,689
Closed -$2.01M – 147
2024
Q4 		$2.01M Sell
5,689
-80
-1% -$29.4K 0.48% 91
2024
Q3 		$2.07M Buy
+5,769
New +$1.95M 0.49% 92

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Dorsey Wright & Associates's UTHR Position: Q2 2026 in Review

Dorsey Wright & Associates reduced its United Therapeutics (UTHR) stake by 51% in Q2 2026, selling an estimated $3.16M and leaving 5,354 shares worth $2.9M. The position accounts for 0.49% of the portfolio, ranked #60.

Dorsey Wright & Associates first reported a position in UTHR in Q3 2024 and has held it in 5 quarters since. The position peaked at $6.5M in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Dorsey Wright & Associates held 5,354 shares of United Therapeutics worth $2.9M as of Q2 2026.
  • Dorsey Wright & Associates sold 5,613 United Therapeutics shares in Q2 2026, an estimated $3.16M.
  • United Therapeutics made up 0.49% of Dorsey Wright & Associates's portfolio in Q2 2026, its #60 holding.
  • Dorsey Wright & Associates first reported a position in United Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Dorsey Wright & Associates's United Therapeutics position peaked at $6.5M in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Dorsey Wright & Associates's 13F filing for Q2 2026, filed 6 Aug 2026.